Merck KGaA agreed to acquire Silence Therapeutics in a deal valued at $1.3 billion, aiming to build out its genetic-medicines presence in rare and specialty diseases. The acquisition expands Merck KGaA’s siRNA capabilities, with Silence’s pipeline centered on divesiran, an investigational siRNA therapy. The transaction underscores how large pharma continues to consolidate late-stage and platform-focused RNA interference assets rather than build capabilities from scratch. For Merck KGaA, the focus remains on translating genetic targeting into clinical programs with differentiated dosing and patient populations. Industry attention will turn to how Merck KGaA integrates Silence’s development plans and whether it accelerates the advancement of divesiran and the broader siRNA pipeline under its governance.